ReviewFrontiers in oncology2022

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer.

Ofek Mussafi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.